Navigation Links
Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis
Date:6/13/2013

p> Disease
Improvement /
Activity Measure24-WeekResponders/Total
Patients (Percent
Responders)52-WeekResponders/Total
Patients (Percent
Responders)ACR20

149/201 (74%)

139/196 (71%)ACR50

83/201 (41%)

96/197 (49%)ACR70

43/201 (21%)

53/197 (27%)CDAI Remission

34/200 (17%)

40/195 (21%)SDAI Remission

30/195 (15%)

42/194 (22%)DAS28 ESR <2.6

35/200 (18%)

47/195 (24%)DAS28 ESR </= 3.2

55/200 (28%)

82/195 (42%)DAS28 CRP <2.6

59/195 (30%)

80/194 (41%)DAS28 CRP </= 3.2

93/195 (48%)

116/194 (60%)Boolean Remission

19/195 (10%)

32/194 (16%) Safety ResultsSafety signals observed during the open-label extension were consistent with previously reported results of baricitinib. Among patients who remained on the 4 mg dose, treatment-emergent adverse events (TEAEs) occurred in 57 (53 percent); serious adverse events (SAEs) in 11 (10 percent); infections in 34 (31 percent); and serious infections in four (4 percent). Among patients who received the 8 mg dose, TEAEs occurred in 59 (63 percent); SAEs in eight (9 percent); infections in 37 (40 percent); and serious infections in two (2 percent). No opportunistic infections or tuberculosis cases were observed. There was one death in the 8 mg group due to a suspected myocardial infarction.

"In this clinical trial baricitinib showed statistically and clinically significant improvements in the features of this condition, which were maintained throughout a year of treatment. To date, baricitinib has demonstrated an acceptable safety profile and side effects have generally been straightforward to manage. These encouraging findings support further investigation of this new drug in rheumatoid arthritis," said Peter Taylor, M.A., Ph.D., F.R.C.P., Norman Collisson Chair of Musculoskele
'/>"/>

SOURCE Eli Lilly and Company; Incyte Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Lilly to Present at Goldman Sachs Global Healthcare Conference
2. Lilly Acquires Novel Tau Tangle Diagnostic Program to Bolster Alzheimers Disease Research and Development
3. Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Including MRI Results, in Patients with Rheumatoid Arthritis
4. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and the May 6, 2013 Lead Plaintiff Deadline
5. Todays Research on Incyte and Arena Pharma: Biotech Stocks Up on Drug Approvals
6. Steep Hill Laboratories and Halent Scientific Proudly Announce Historic Merger
7. Andain Inc. Announces 2,000 Units Initial Production of the Breakthrough Miniature Disposable Insulin Pump for Use in Clinical Trials for Type-I and Type-II Diabetes
8. Verenium Announces Appointment Of Brian Carter As Vice President Of Grain Processing
9. Neogen announces Bohannon retirement, successor named
10. BioDelivery Sciences Announces NDA Submission for BUNAVAIL on Track Following Positive Pre-NDA Meeting with FDA
11. Hemostemix Announces Formation of Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... 31, 2015 , ... Ralco is honored to announce that it is the ... be held August 5-9 in Marshall. The Ralco Enrichment Center is an interactive experience ... agriculture impacts their daily lives. This unique exhibit also features a birthing center for ...
(Date:7/30/2015)... 30, 2015   GenoSpace , a leading ... and analysis of genomic and other biomedical data, ... joined the company as Vice President of Sales ... "GenoSpace partners with its ... analyze and explore complex sets of genomic, phenotypic ...
(Date:7/30/2015)... ... July 30, 2015 , ... The 2015 Market Research Report on ... current state of the global Propanol market with a focus on the Chinese situation. ... Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang ...
(Date:7/30/2015)... CA (PRWEB) , ... July 30, 2015 , ... ... successful completion of a field clinical study of its canine osteoarthritis stem cell ... with Aratana Therapeutics (Kansas City, KS) and will be marketed in the US ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3
... CAMBRIDGE, Massachusetts and LAUSANNE, Switzerland, August ... ), a drug development company focused on,developing proprietary ... a group of companies with a focus on ... needs today announced that they,have entered into a ...
... /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI ... the second quarter ended June 30, 2009. , "We ... Proprietary Medical Products business during the quarter, including continued ... lines," said Dr. William Hunter, President and CEO of ...
... ... Two Decades of Cardiovascular Core Lab Experience , ... Rochester, NY (PRWEB) August 6, 2009 -- iCardiac Technologies , Inc., ... has expanded its sales and marketing team by hiring Susan Boyle as Senior Director of ...
Cached Biology Technology:Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305 2Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305 3Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305 4Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305 5Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305 6Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 2Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 3Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 4Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 5Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 6Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 7Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 8Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 9Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 10Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 11Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 12Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 13Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 14Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 15Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 16Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 17Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 18Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 19Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 20Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 21Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 22Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 23Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 24Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 25Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 26Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 27Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009 28iCardiac Expands Sales and Marketing Team 2
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. ... a biometric authentication company focused on the growing ... smart wallet, announces that it has filed provisional ... and Method. This invention highlights ... only authorizes an account, but also the user ...
(Date:7/13/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market, announced ... for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... secure method to make payments.  With this patent, ... with its groundbreaking voice-direct payment patent application, with ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced a new Match-in-Sensor™ ... hardware encapsulated fingerprint sensor and matching solution. ... literally off the grid, isolating fingerprint image ... the fingerprint sensor to provide ultimate protection ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... quartet of studies by researchers at the California Institute ... regulatory networks recently published in the Proceedings of ... The collection of papers, "Gene Networks in Development ... Caltech,s Eric H. Davidson, the Norman Chandler Professor of ...
... -- In the journal Estuarine, Coastal and Shelf Science ... Science Professor Dr. Peter Glynn, and 2008 Pew Fellow for ... than 25 years of data on reef ecosystems recovery from ... which corals expel their symbiotic algal partners and turn pale ...
... Researchers at the Swiss Institute of Bioinformatics and the ... Oncology in Lausanne have developed a new test to ... could help change how treatment is delivered in the ... resistance to neoadjuvant chemotherapy in breast cancer, i, published ...
Cached Biology News:Caltech researchers help unlock the secrets of gene regulatory networks 2Long-term recovery of reefs from bleaching requires local action to increase resilience 2Stroma genomic signature predicts resistance to anthracyclin-based chemotherapy in breast cancer 2Stroma genomic signature predicts resistance to anthracyclin-based chemotherapy in breast cancer 3
Estrogen Receptor (ER) Competitor Assay Kits Green for Estrogen Receptors-alpha and -beta (ER-Alpha and ER-Beta) are ideal for screening novel estrogen receptor binding compounds and endocrine disrup...
Collected from 8-12 week old sexually mature rats. Pricing: $100/unit for 1 - 10 units...
Mouse Aminopeptidase P2/XPNPEP2 Affinity Purified PAb Protein Family: Aminopeptidases, Metalloproteases...
... 53 new primer sets added in Dec 2005 ... 3 hours , Detection from as ... , Specific primers available for hundreds of ... real-time or end-point RT-PCR , Ideal ...
Biology Products: